Showing results (271-280 of 556) with videos related to

Sort By:
Pageof 56
Journal of Medical Economics|October 10, 2013
Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)Donna Lawrence, Michael Maschio, Kevin J Leahy, et al.
Population Health Management|November 30, 2020
Evaluation of Risk Factors for Hepatitis C Virus Infection Among Philadelphia's Shelter-Bound, Homeless Population: Data from a Student-Run Hepatitis C Virus Screening InitiativeMichelle Leach, Sara Chapin, Ilana Porges, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 9, 2002
Health economic evaluations: the special case of end-stage renal disease treatmentWolfgang C Winkelmayer, Milton C Weinstein, Murray A Mittleman, et al.
JAMA|January 19, 1990
Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertensionJ T Edelson, M C Weinstein, A N Tosteson, et al.
Health Economics|May 6, 2004
When does quality-adjusting life-years matter in cost-effectiveness analysis?Richard H Chapman, Marc Berger, Milton C Weinstein, et al.
Cancer Research|September 1, 1989
Relationship between cell membrane potential and natural killer cell cytolysis in human hepatocellular carcinoma cellsD Stevenson, R Binggeli, R C Weinstein, et al.
American Heart Journal|April 26, 2001
Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levelsJ Tsevat, K M Kuntz, E J Orav, et al.
Plos One|December 31, 2016
Sustainable Development in Surgery: The Health, Poverty, and Equity Impacts of Charitable Surgery in UgandaMark G Shrime, Serufusa Sekidde, Allison Linden, et al.
Pediatrics|January 2, 2003
Cost-effectiveness analysis of predischarge monitoring for apnea of prematurityJohn A F Zupancic, Douglas K Richardson, Bernie J O'Brien, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 11, 2009
Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United StatesAmy K O'Sullivan, Ankur Pandya, George Papadopoulos, et al.
Pageof 56